Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Lymphoid Hematologic Malignancy Clinical Trial

Official title: Open Label Phase II Study of Ixazomib for the Prevention of Recurrent or Late Acute and Chronic Graft-versus-Host Disease at 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies

Status Completed

Clinical Trial Summary

This is a single arm open label phase 2 study evaluating the potential effect of ixazomib on the prevention of recurrent or late acute graft-versus-host disease (GVHD) and chronic GVHD at 1-year following reduced intensity (RI) or non-myeloablative (NMA) allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of hematologic malignancies.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Graft vs Host Disease
• Hematologic Neoplasms
• Lymphoid Hematologic Malignancy
• Myeloid Hematologic Malignancy
• Neoplasms

• NCT number: NCT03082677
• Study type: Interventional
• Source: Memorial Sloan Kettering Cancer Center
• Status: Completed
• Phase: Phase 2
• Start date: March 10, 2017
• Completion date: September 2, 2021